NEOIMMUNETECH, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,600 KRW | -2.68% |
|
-0.81% | -20.99% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 203,671 | 78,963 | 40,041 |
| Enterprise Value (EV) 1 | 54,995 | -33,261 | -25,123 |
| P/E ratio | -18.8 x | -6.53 x | -3.75 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | -1.1 x | 0.6 x | 0.48 x |
| EV / FCF | -2,150,059 x | 1,152,680 x | 652,543 x |
| FCF Yield | -0% | 0% | 0% |
| Price to Book | 31.5 x | 16.5 x | 13.4 x |
| Nbr of stocks (in thousands) | 19,678 | 19,765 | 19,773 |
| Reference price 2 | 10,350 | 3,995 | 2,025 |
| Announcement Date | 3/18/22 | 3/23/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -7,292 | -15,443 | -30,282 | -50,033 | -55,380 | -52,637 |
| EBIT 1 | -7,677 | -16,224 | -31,270 | -51,906 | -58,182 | -55,847 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -7,043 | -14,193 | -30,429 | -52,413 | -60,289 | -53,303 |
| Net income 1 | -7,043 | -14,198 | -30,456 | -52,482 | -60,406 | -53,405 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -122.5 | -174.4 | -368.5 | -550.9 | -611.6 | -540.3 |
| Free Cash Flow | - | -9,435 | -21,632 | -25,579 | -28,855 | -38,500 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 1/8/21 | 1/8/21 | 3/23/21 | 3/18/22 | 3/23/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 46,871 | 105,230 | 68,311 | 148,676 | 112,224 | 65,164 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | -9,435 | -21,632 | -25,579 | -28,855 | -38,500 |
| ROE (net income / shareholders' equity) | - | -16.7% | -30.4% | -42.6% | -42.9% | -54.9% |
| ROA (Net income/ Total Assets) | - | -11.5% | -18% | -23% | -22.2% | -30.3% |
| Assets 1 | - | 123,298 | 169,016 | 228,649 | 271,509 | 176,242 |
| Book Value Per Share 2 | 924.0 | 282.0 | 204.0 | 329.0 | 242.0 | 151.0 |
| Cash Flow per Share 2 | 802.0 | 248.0 | 172.0 | 313.0 | 234.0 | 139.0 |
| Capex 1 | 57.9 | 433 | 1,087 | 2,710 | 2,477 | 791 |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 1/8/21 | 1/8/21 | 3/23/21 | 3/18/22 | 3/23/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -20.99% | 22.96M | |
| +15.20% | 121B | |
| +19.67% | 113B | |
| +18.95% | 26.02B | |
| -23.86% | 19.39B | |
| -19.03% | 15.91B | |
| -20.90% | 15.09B | |
| -46.14% | 15.06B | |
| +63.85% | 14.93B | |
| +4.49% | 13.85B |
- Stock Market
- Equities
- A950220 Stock
- Financials NeoImmuneTech, Inc.
